Dr John Maher at Kings College London came to Worldwide Cancer Research with a bright idea for a brand new type of immunotherapy. This new therapy was rapidly taken to clinical trials and it has proven to be successful at treating patients with head and neck cancer.

New lifesaving immunotherapy

In 2008, Dr John Maher came to us looking to get started on a research idea involving turning the immune system against cancer. Within 5 years, John had made a crucial discovery that allowed his team to develop a brand new type of immunotherapy. This new therapy was rapidly taken into clinical trials where, even in its early stages, has shown real promise and has even helped cure one patient who was handed a terminal diagnosis by his doctors.

In the labs at King’s College London, scientists are cooking up new ways to tackle cancer. Men and women in white coats sit at sterile isolation hoods, tinkering with white blood cells, the cells of our immune system that protect us from infection, to exploit their seek and destroy capabilities as a weapon against cancer. Dr John Maher has been leading a team here since 2004, where he has been pushing forward new approaches for turning the patient’s own immune system against cancer.

In 2008, John started on Worldwide Cancer Research funded project to see if they could find a way to make a type of immunotherapy called CAR T-cell therapy, which had previously only been shown to be effective in blood cancer, work for solid tumours.

CAR T-cell therapy has proven to be a game changer in the treatment of blood cancers. However, impact on solid tumours, such as lung or prostate, has been less impressive. This represents the next frontier in the clinical development of this new type of cancer treatment

CAR T-cell therapy is called a ‘living drug’. In practice, a sample of a patient’s blood is taken to a lab where the white blood cells are isolated and extracted. Scientists then insert new genes into the white blood cells using a harmful virus. The new genes give the white blood cells the ability to recognise cancer cells as they would bacteria or virus, allowing them to mount a coordinated and sustained attack against the cancer. The genetically modified white blood cells are then nurtured in the lab to grow and divide until enough have been produced to be injected back into the patient.

In 2013, John’s research led to a discovery that allowed his team to develop a brand new type of CAR T-cell therapy. They immediately started planning their own clinical trial to test the therapy in patients. This clinical trial has already shown real promise and has even helped cure one patient, James, who was handed a terminal diagnosis by his doctors.

James was diagnosed with neck cancer in 2012. He was told to prepare himself for the worst. After three surgeries, radiotherapy and chemotherapy, there were no other options. He faced his terminal diagnosis with bravery, strength – and most importantly – hope. After searching online for help, James found out about John and the new trial he was setting up. John instantly wanted to help and got James enrolled on the trial.

John’s unique CAR T-cell therapy, developed through his Worldwide Cancer Research project, was designed to recognise and attack a feature of cancer cells common in many types of solid tumour, including head and neck cancer. James eventually enrolled onto John’s clinical trial and began receiving treatment. Amazingly, James’s tumour started to shrink.

However, James’s cancer did come back so he enrolled on to a different clinical trial for a drug called a PD-1 inhibitor. These drugs are designed to release the brake on the immune system put in place by cancer cells. James reaction to the treatment was remarkable and John believes it is due to a combination of the treatments he has received. He thinks that releasing the brake on James’s immune system ‘woke up’ the CAR T-cell therapy he had received on his trial and provoked the cancer killing white blood cells to attack his tumour.

John’s trial is ongoing and if they see more success, as they have with James and other patients involved in the trial, they hope that they will be able to take their new therapy into larger clinical trials on the road to getting it approved for patients.

We are extremely grateful to the kindness of the supporters of Worldwide Cancer Research for funding our research. An Improved understanding of cancer and development of better treatments for these diseases relies fundamentally on your generosity.

Breakthroughs like Dr John Maher's are only possible because of your kindness and generosity. Your support backs scientists like John to pursue their idea and make a start on finding new cures for cancer. 


Join our monthly newsletter

Keep up to date with all our latest news, events, groundbreaking research discoveries and much more!

You're now a Curestarter!

Our newsletter usually drops towards the end of each month

Thanks for subscribing